Consultations with the MHRA have begun for BCV to obtain UK CMA. The company will concurrently complete the global Phase III trial as quickly as possible to accelerate access to global markets. Impact on the fiscal year ending December 2026 consolidated results is unknown\/not disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4582-20261006-01.pdf","jir_short_summary":"Consultations with the MHRA have begun for BCV to obtain UK CMA. The company will concurrently complete the global Phase III trial as quickly as possible to accelerate access to global markets. Impact on the fiscal year ending December 2026 consolidated results is unknown\/not disclosed.","jir_summary":"### Key Points\nSymBio Pharmaceuticals has initiated consultations with the UK MHRA for obtaining Conditional Marketing Authorization (CMA) for Brincidofovir (BCV). CMA is a system that allows earlier market access for patients with serious unmet needs, and the company plans to proceed in parallel with completing the ongoing global Phase III clinical trial. Through dialogue with regulatory authorities, the company aims for expedited market access when clinical benefit is judged to outweigh risks despite some data uncertainty. Impact on consolidated results for the fiscal year ending December 2026 has not been disclosed.\n\n### Outlook and Strategy\nThe company is pursuing a strategy to accelerate global expansion of BCV across three therapeutic areas (post-transplant viral infections, oncology, and neurological disorders). By securing early market access via CMA while completing the ongoing global Phase III trial and strengthening collaboration with regulatory authorities, the company aims to shorten the lead time to market launch.","jir_financial_highlights":"Impact on consolidated earnings guidance: Unknown (Unknown)\nProgress of global Phase III clinical trial: 30 patients enrolled (as of 2026\/9\/17) (Targets: 69 patients by end of 2026, 180 patients by end of 2027)\nCMA acquisition process: Initiated (Newly initiated)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #BCV, #CMA, #ClinicalTrials, #UKRegulatory","jir_key_figures":"Number of enrolled patients as of 2026\/9\/17: 30 patients\nEnrollment targets: 69 patients by end of 2026, 180 patients by end of 2027\nCurrent impact: Impact on consolidated earnings guidance is Unknown","jir_meta_title":"SymBio Pharmaceuticals: Initiates Consultations for UK CMA\uff5cBCV Clinical Development Progress and Year-End 2026 Targets","jir_meta_description":"SymBio Pharmaceuticals has started consultations for BCV's UK CMA. Disclosed are progress of the ongoing global Phase III trial and plans to strengthen collaboration with regulatory authorities. Impact on the fiscal year ending December 2026 is TBD.","jir_og_title":"SymBio Pharmaceuticals Initiates Consultations for UK CMA\uff5cBCV Clinical Development Progress","jir_og_description":"Initiation of consultations for BCV's UK CMA. Strengthening collaboration with regulatory authorities and advancing the Phase III trial to pursue early access to global markets.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-127625","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n